Avacta looks for financial growth
Donnerstag, 23 April 2009
Advanced bioscience firm Avacta has announced the details of a new method of clinical analysis, which it says could revolutionise the market.
The Optim product is a laboratory-based instrument capable of minute analysis of small biological samples.
In particular, the firm believes it will help developers attain vital information about products in the early stages of their development, accelerating the bringing of new drugs to the market.
Avacta has endured a torrid few months of trading, recording first half losses of £972,000.
It hopes that the new technology will mark a turning point for business, allowing it to transform from a university spin-out into a viable business.
Chief executive Alastair Smith said: "Optim is the first in a range of high value analytical products for the biopharmaceutical sector which Avacta has under development and we believe that the substantial benefits it has to offer to end users are very clear."
In February, Avacta acquired YorkTest Veterinary Services, a York-based veterinary laboratory business.
© Adfero Ltd